Expand, Conquer
Growing Demand for IV Fluids
The demand for intravenous (IV) fluids is projected to surge from 24 million liters in 2021 to over 100 million liters by 2035. This sharp increase is driven by the growing number of surgical procedures, rising cases of dehydration due to climate and water issues, and a global uptick in chronic illnesses like cancer and kidney disease. As healthcare systems expand and modernize, especially in developing regions, the need for reliable access to these essential fluids is becoming more critical than ever, placing pressure on manufacturers and medical suppliers to scale production.
24+
Million Litters was required in 2021
100+
Million Litters will be required in 2025
A Strategic Healthcare Imperative in Ethiopia
Rising Need for Specialized Drugs
Ophthalmic medications and dialysis solutions are in growing demand across Ethiopia, driven by the increasing prevalence of chronic kidney disease and vision-related conditions. The rise of non-communicable diseases, combined with limited access to early diagnosis and sustained treatment, has created an urgent need for specialized pharmaceutical interventions. These products not only support survival but also improve long-term health outcomes and quality of life.
Growing Disease Burden - Every stage—from raw material sourcing to packaging—is tightly controlled for consistency and safety. Critical Treatment Role - Equipped with cutting-edge technology and operated by highly trained professionals. Gap in Local Access - Ongoing investment in compliance, innovation, and continuous improvement. Market Opportunity - Earned reputation for reliability among healthcare providers, institutions, and communities.Ethiopian Pharmaceutical Manufacturing
Reducing Dependency and Building Resilience
Ophthalmic medications and dialysis solutions are in growing demand across Ethiopia, driven by the increasing prevalence of chronic kidney disease and vision-related conditions. The rise of non-communicable diseases, combined with limited access to early diagnosis and sustained treatment, has created an urgent need for specialized pharmaceutical interventions. These products not only support survival but also improve long-term health outcomes and quality of life.
Import Dependency: ~70% of Ethiopia’s pharmaceutical supply is still imported. Public Procurement Advantage: 25% price preference granted to local manufacturers. Government Incentives: Includes tax breaks, regulatory easing, and industry-specific reforms. Strategic Opportunity: Local production reduces forex pressure, improves access, and enables regional scale-up.